Skip to content
Clinical Trials – home
Therapeutic area

Hepatobiliary disorders – page 26

  • 356 clinical trials
  • 141 recruiting
  • 239 conditions
  • 25 countries

Conditions in this area

239 conditions with trials, the busiest first

Clinical trials in Hepatobiliary disorders

356 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

356 clinical trials

Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Biocompatibles UK Limited
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pyridoxine Hydrochloride
  • Sponsor:Oslo University Hospital HF
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bi 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Translational Research In Oncology
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enoxaparin Sodium
  • Sponsor:European Foundation For The Study Of Chronic Liver Failure

Chronic hepatitis B+1

Not recruiting
Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Mikrobiomik Healthcare Company S.L.

Substances studied in this area

The therapies tested most often in Hepatobiliary disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.